Imugene Limited

Imugene Limited is a clinical-stage immuno-oncology company based in Sydney, Australia, dedicated to developing innovative treatments that activate the immune system to fight cancer. Their diverse portfolio includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating various cancers in combination with standard of care drugs and emerging immunotherapies like CAR T's.

Imugene's focus is on harnessing the body's natural defenses to combat cancer. They are developing off-the-shelf (allogeneic) cell therapy CAR T drugs, like Azer-Cel, that target CD19 to treat blood cancers. Their onCARlytics technology combines the CF33 oncolytic virus with CD19 antigen delivery to target solid tumors that are difficult to treat with CAR T therapy alone. Imugene's dedication to innovation and their unique platform technology positions them as a key player in the rapidly advancing field of immuno-oncology.

Imugene is a clinical-stage immuno-oncology company dedicated to developing transformative cancer medicines that improve patients' lives. They strive to activate the immune system of cancer patients to identify and eradicate tumors, working with a leading team of international cancer experts to create innovative and effective treatments.

Imugene's culture is driven by innovation, patient-centricity, collaboration, integrity, and excellence. They encourage bold thinking, creativity, and bravery in their work, always prioritizing the needs of patients. They foster strong relationships with top experts in the field, uphold ethical scientific practices, and strive for outstanding quality in all aspects of their operations.